MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
Tuesday, July 7, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: MeiraGTx has announced a strategic investment of $400 million from Oberland Capital, which includes $375 million in non-dilutive cash and $25 million in equity. This funding aims to support the development and commercialization of AAV2-hAQP1, a treatment for late radiation-induced xerostomia. Following regulatory approval, Oberland Capital will receive capped royalties on net sales of the product.
Price reaction · baseline $13.89 (2026-07-06 close) · hit pre-market · clean, no other MGTX news in the window
day 0 close · peak
+5.5%
day 1
+1.8%
day 3
-3.6%
Market Sentiment Analysis
POSITIVE FACTORS
MeiraGTx secures a significant $400 million investment.
Funding supports the development of innovative therapies.
Oberland Capital's involvement indicates confidence in MeiraGTx's pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~11 mo
Medium dilution risk
Lead asset
Allogeneic T cell progenitors, cultured ex-vivo
Phase 1 · Hematological Malignancies
Full Press Release Details
MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia
Frequently Asked Questions
What is the total investment amount from Oberland Capital?
Oberland Capital is investing a total of $400 million in MeiraGTx.
What will the investment support?
The investment will support the development and commercialization of AAV2-hAQP1.
What condition does AAV2-hAQP1 aim to treat?
AAV2-hAQP1 is designed to treat grade 2/3 late radiation-induced xerostomia.
What type of royalties will Oberland Capital receive?
Oberland Capital will receive low single-digit capped royalties on net sales.